Securities code: Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) securities abbreviation: Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) Announcement No.: 2022016 Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937)
2021 annual performance express and performance forecast amendment announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
(I) performance forecast period: January 1, 2021 to December 31, 2021
(II) previous performance forecast
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) (hereinafter referred to as “the company”) predicted the operating performance in 2021 in the performance forecast for 2021 disclosed on January 28, 2022: the change range of net profit attributable to shareholders of Listed Companies in 2021 is RMB 11-13 million, and the change range of net profit after deducting non recurring profits and losses is RMB 1.5-1.7 million.
(III) revised expected performance
Expected performance: □ turning losses into profits □ rising and falling in the same direction
Whether the current reporting period is the same period of last year
The original estimate and the latest estimate are positive
Profit: 11 million yuan – 6.3 million yuan – 6.5 million yuan
RMB 13 million attributable to listed companies
Profit:
Shareholders of the company
Decrease over the same period of last year: decrease over the same period of last year: 54.02 million yuan
Net profit
75.93%-79.64% 87.97%-88.34%
Deducting non recurring profit: 1.5 million yuan – loss: 1.8 million yuan – 2 million profit:
yes
1.7 million yuan and 51.82 million yuan after profit and loss
Net profit decreased over the same period of last year:
96.72% – 97.11% not applicable
Note: “ten thousand yuan” in this announcement refers to ten thousand yuan.
(IV) main data and indicators in 2021
Unit: RMB
Increase and decrease of the project in the same period of last year in the reporting period
Total operating income 340058072617279013394028 21.88%
Operating profit 9262003366119055190 – 84.86%
Total profit 8124297596182935972 – 86.86%
Net profit attributable to shareholders of listed companies 640 Zhuhai Bojay Electronics Co.Ltd(002975) 5401771766 – 88.15%
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses -1960213695182303237 – 103.78%
Basic earnings per share 0.07 0.75 – 90.67%
Weighted average return on net assets 0.85% – 10.75% – 9.9%
Increase and decrease at the end of the reporting period
Total assets 11870686059083937868705 41.42%
Owner’s equity attributable to shareholders of listed companies 7735084370051802424168 49.32% total
Share capital 95666682007175001100 33.33%
Net assets per share attributable to shareholders of listed companies 8.09 7.22 12.05%
2、 Description of operating performance and financial status
During the reporting period, the company realized an operating revenue of 340058072617 yuan, an increase of 21.88% over the same period of last year; The operating profit was 926200336 yuan, a decrease of 84.86% over the same period of last year; The total profit was 812429759 yuan, a decrease of 86.86% over the same period of last year; The net profit attributable to shareholders of the listed company was 640 Zhuhai Bojay Electronics Co.Ltd(002975) yuan, a decrease of 88.15% over the same period of the previous year, and the net profit attributable to shareholders of the listed company after deducting non recurring profits and losses was -196021369 yuan, a decrease of 103.78% over the same period of the previous year.
The reasons for the increase or decrease of the company’s operating profit, total profit, net profit attributable to shareholders of the listed company, net profit attributable to shareholders of the listed company after deducting non recurring profits and losses and basic earnings per share of more than 30%:
1. Decrease in gross profit margin
When the decrease of gross profit rate leads to the increase of income, the gross profit decreases by about 39 million yuan. On the one hand, due to the continuous impact of the epidemic, the pharmaceutical circulation and marketing market outside the hospital has changed, and the sales categories of pharmacies have been strictly controlled. At the same time, the public’s demand for colds, antibiotics and other drugs has decreased, resulting in weak sales growth of key varieties such as colds and fever operated by the company. On the other hand, in order to continuously expand market share, the company continues to increase promotion investment in the process of business development. In 2021, the company’s sales allowance increased by about 45 million yuan over the previous year, with an increase rate of about 116%.
2. Increase in expenses during the period
During this period, the expenses increased by about 45 million yuan, and the increase of expenses exceeded the increase of income. Among them, the sales expense increased by about 27.2 million yuan, but under the background of continuous growth of revenue scale, the growth rate of sales expense rate decreased, and the scale effect based on infrastructure such as self owned warehouses and transport vehicles gradually appeared. The administrative expenses increased by about 19.6 million yuan, and the R & D expenses increased by about 4 million yuan. The company fully implements the digital intelligence development direction of the pharmaceutical industry and increases investment in technology. The company set up technology center in the first half of 2021, and gathered nearly 100 technical team, which is based on Algorithm Engineer and system architect. At present, the construction of the medical intelligence research center of intelligent technology based on Internet plus artificial intelligence + big data has been completed. The intelligent decision engine of pharmaceutical industry has been established and improved, and the investment has been invested about 13 million yuan.
3. Business layout and expansion
The company actively expands its business layout on the basis of existing “pharmaceutical circulation + Internet”. In 2021, Sichuan jinpeifang Pharmaceutical Co., Ltd., Chengdu Shenniao Internet hospital Co., Ltd., Hainan meidikang Biotechnology Co., Ltd. and other holding subsidiaries were successively established, holding Sichuan Jingcheng famous medical Co., Ltd. and taking shares in Sichuan Yuxin traditional Chinese medicine family medicine chain Co., Ltd. and constantly exploring in drug production approval, pharmaceutical e-commerce, new retail, C-end emerging traffic, medical resources and IP building, Strive to realize the integration of B and C terminals
Exhibition, precise empowerment, and further build a full chain pharmaceutical service ecosystem in the off-site market. The new business segment has not generated revenue in the initial stage. In addition, the traditional Chinese medicine decoction piece factory was officially put into operation in August 2021, the scale effect has not yet appeared, the production cost is high, and there are also large losses this year. The above factors resulted in a profit reduction of about 10 million yuan.
3、 Communication with accounting firms
The relevant data of the company’s previous performance forecast in 2021 is the result of the preliminary communication between the company’s financial department and the annual report accounting firm after preliminary calculation, but has not been audited by the accounting firm. The company has further communicated and confirmed with the accounting firm on matters related to the revision of the performance forecast. Considering the current annual report review
According to the work progress, as of the disclosure date of this announcement, there is no difference between the company and the accounting firm in terms of performance in the reporting period.
4、 Explanation of performance correction reasons
Combined with the promotion of the company’s audit work in 2021, based on the principle of prudence, after in-depth communication with the accounting firm, the deviation between the accounting treatment of some business activities of the company and the previous notice of the company was corrected, resulting in differences in the net profit attributable to the shareholders of the listed company and the net profit after deducting non recurring profits and losses.
The main amendments are as follows:
1. The subsidy for the construction project of “supply chain integrated service platform” of Chengdu Finance Bureau is 3 million yuan, which was originally recognized as income related government subsidy by the company and included in other income at one time; Based on the principle of prudence, the government subsidy recognized as asset related is adjusted and amortized by 12 years, so the other income is reduced by 2.75 million yuan; 2. Based on the principle of prudence, the bad debt provision of 1.9 million yuan is made for the company’s receivables;
3. Henan Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) Hezong Pharmaceutical Co., Ltd. which was not transferred in March 2021 at the time of the previous performance forecast
The loss of 396000 yuan from January to March 2021 was included in the consolidation scope;
4. In the previous performance forecast, the purchase rebate was increased by 100800 yuan, so the main business cost was increased by 100800 yuan.
5、 Other relevant instructions
1. The board of directors of the company sincerely apologizes for the inconvenience caused to the majority of investors by the revision of the performance forecast. The company will analyze the reasons for the revision of this performance forecast, strengthen the training of relevant personnel in the future work, and strengthen the supervision and audit work in strict accordance with the requirements of laws and regulations such as the company law, the securities law, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for self discipline supervision of listed companies No. 2 – standardized operation of GEM listed companies, so as to further improve the quality of information disclosure.
2. The financial data revised in this performance express and performance forecast have been pre communicated with the audit institution. The specific financial data shall be subject to the 2021 annual report officially disclosed by the company. Please invest carefully and pay attention to risks.
6、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting, the chief accountant (if any) and the person in charge of accounting organization (Accounting Supervisor)
2. Statement of the board of directors on the amendment of the performance forecast of the current period.
It is hereby announced.
Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) board of directors April 17, 2022
